BRIEF published on 06/18/2025 at 07:05, 8 months 17 days ago PHAXIAM Therapeutics suspends trading of its shares Euronext Paris Innovative Treatments PHAXIAM Suspension Of Quotation Delisting Securities
PRESS RELEASE published on 06/18/2025 at 07:00, 8 months 17 days ago Inside Information / Other news releases PHAXIAM Therapeutics suspends trading shares for delisting on Euronext Paris market. No reimbursement to shareholders. Company focuses on innovative phage-based treatments for resistant bacterial infections Trading Delisting Suspension PHAXIAM Therapeutics Phage-based Treatments
BRIEF published on 06/05/2025 at 07:05, 9 months ago PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement Biopharmaceuticals Judicial Liquidation Court Hearing PHAXIAM Therapeutics Euronext Delisting
PRESS RELEASE published on 06/05/2025 at 07:00, 9 months ago Inside Information / Other news releases PHAXIAM Therapeutics announces new postponement of Offer Review Hearing by Lyon Commercial Court to June 11, 2025. Company to request delisting from Euronext Euronext Delisting Postponement PHAXIAM Therapeutics Lyon Commercial Court
BRIEF published on 03/14/2025 at 17:50, 11 months 21 days ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
PRESS RELEASE published on 03/14/2025 at 17:45, 11 months 21 days ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
BRIEF published on 03/06/2025 at 18:01, 11 months 29 days ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 11 months 29 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 11 months 30 days ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 12/30/2024 at 17:50, 1 year 2 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
Published on 03/05/2026 at 13:40, 15 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 25 minutes ago Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 13:30, 25 minutes ago Nextech3D.ai Expands AI Event Technology Into New Markets and Implements 20%-30% Enterprise Price Increase
Published on 03/05/2026 at 13:00, 55 minutes ago Revolve Signs Definitive Agreements for Portfolio of 16 Distributed Generation Solar Projects in Mexico
Published on 03/05/2026 at 13:00, 55 minutes ago Field Work Identifies New Mineralized Trend and Additional Gold Targets at Golden Rose
Published on 03/05/2026 at 13:43, 12 minutes ago Healthcare specialist SHS Capital exits AMW, a leading specialty pharma company, and continues partnership by reinvesting with its current fund as part of a syndicate of investors
Published on 03/05/2026 at 13:25, 30 minutes ago Huawei and SOLUM Unveil Shop-in-Shop Smart Converged Network Solution to Accelerate Retail Intelligence
Published on 03/05/2026 at 13:06, 48 minutes ago HENSOLDT acquires Nedinsco and expands its European presence
Published on 03/05/2026 at 13:05, 50 minutes ago Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales
Published on 03/05/2026 at 13:00, 55 minutes ago Huawei Launches AI Data Platform to Bridge Models and Business Value
Published on 03/04/2026 at 23:50, 14 hours 5 minutes ago Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 19 hours 55 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 20 hours 10 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
